Savara inc.SVRA.US Overview

US StockHealthcare

(No presentation for SVRA)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

SVRA Overall Performance

SVRA AI Analysis & Strategy

SVRA Recent Performance

0.97%

Savara inc.

0.81%

Avg of Sector

-1.14%

S&P500

SVRA PowerScanner

SVRA Key Information

SVRA Valuation Metrics

SVRA Earnings Table

SVRA Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.